Concepedia

Dan Howard

DH

Statistics

Publications

18

Citations

902

H-Index

17

Active since

2007

Affiliations

Novartis (United States)(Current)

Novartis (Switzerland)

Novartis (France)

Boston Biomedical Research Institute

Tris Pharma (United States)

Dan Howard is an author at Novartis (United States) specializing in pharmacology, clinical pharmacology, and pharmacokinetics.

Publications per year

2007–2013

18

Publications

18

Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans

Handan He, Phi Tran, Hequn Yin et al. · Drug Metabolism and Disposition · 2008 · 139 citations

, , +8

Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P‐Glycoprotein in the Disposition of Aliskiren

Sujata Vaidyanathan, Gian Camenisch, Helmut Schuetz et al. · The Journal of Clinical Pharmacology · 2008 · 103 citations

, , +13

The Absolute Oral Bioavailability and??Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers

Yanling He, Brian M. Sadler, Ron Sabo et al. · Clinical Pharmacokinetics · 2007 · 74 citations

, , +17

Pharmacokinetics of the Oral Direct??Renin Inhibitor Aliskiren Alone and??in Combination with Irbesartan in??Renal Impairment

Sujata Vaidyanathan, Hilde Bigler, C M Yeh et al. · Clinical Pharmacokinetics · 2007 · 67 citations

, , +16

The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers

Yanling He, Ron Sabo, Joelle Campestrini et al. · British Journal of Clinical Pharmacology · 2007 · 65 citations · Full text

, , +14

1–5 of 18